This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
New Targeted Cancer drug raises child leukemia survival
A North American study led by Dr. Kirk Schultz shows the targeted drug imatinib plus chemotherapy doubled three year survival to 87 percent for a rare leukemia in children. The Phase 2 trial at 20 centres, including Vancouver, suggests fewer transplants may be needed.
MENTIONED IN THIS ARTICLE
B.C
B.C. Children's Hospital
Kirk Schultz
Luke
Children's Hospital
Schultz
U.S
National Cancer Institute
National Institutes of Health
Canada
Halifax
Vancouver